BioTuesdays

Tag - AML

ASLAN Pharma gears up for data rich second half

By Len Zehrs ASLAN Pharmaceuticals (NASDAQ:ASLN; TPEx:6497) expects to report topline and interim data in the second half of 2018 from up to four clinical trials with its lead drug candidate, varlitinib, for the...

BioSight developing non-toxic drug against leukemia

By Len Zehr Closely-held BioSight is in clinical development with its lead chemotherapy drug, Astarabine, as a non-toxic treatment for hematologic malignancies, including acute myeloid leukemia (AML). “Treatment and...